Propanc Biopharma, Inc. current report, 17 November 2020

Abrir documento

Business Context and Reporting Period

Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 17, 2020
Principal Event: Implementation of a 1-for-1,000 Reverse Stock Split via a Charter Amendment filed with the Delaware Secretary of State.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on corporate governance and capital structure adjustments.

  • Pre-Split Shares Outstanding (as of Nov 18, 2020): 688,670,618
  • Post-Split Shares Outstanding: 688,671
  • Authorized Common Stock: 1,000,000,000 shares ($0.001 par value)
  • Authorized Preferred Stock: 1,500,005 shares ($0.01 par value)

Material Changes Versus Prior Period

The primary material change is the reduction of outstanding common stock by a factor of 1,000. Key adjustments include:

  • Share Count: Reduced from approximately 688.7 million to 688,671 shares.
  • Trading Symbol: The stock will trade under the ticker "PPCBD" for 20 business days following the effective date.
  • CUSIP Number: Updated to 74346N404.
  • Exchange Status: Trading will commence on the OTC Markets Group Pink Open Market on November 19, 2020.
  • Derivatives: All outstanding options and warrants will be adjusted in accordance with their terms to reflect the split.

Guidance, Outlook, and Management Commentary

Management stated the Reverse Stock Split serves two primary strategic purposes:

  1. Debt Compliance: To maintain legal compliance with outstanding debt and convertible note instruments, specifically regarding obligations to maintain adequate share reserves.
  2. Market Qualification: To increase the per-share trading price to qualify for an uplist to the OTC Markets Group QB Open Market exchange.

Unusual Items/Contingencies: No fractional shares will be issued; instead, stockholders entitled to a fractional share will receive one additional whole share.

Investor Verification Checklist

  • Verify the new CUSIP number (74346N404) and ticker symbol (PPCBD) with your brokerage.
  • Confirm the adjustment of any held options or warrants to ensure they reflect the 1-for-1,000 ratio.
  • Check the specific terms of outstanding debt and convertible notes to understand the impact of the share reserve requirements.
  • Monitor the trading status on November 19, 2020, for the transition to the post-split basis.